Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23958355 | 0.87 | ALOX12 (0.46) | PIK3CDPIK3CBPIK3CARAD52KMT2A | |
| SCHEMBL23958344 | 0.86 | PIK3CD (0.45) | PIK3CDPIK3CBPIK3CARAD52KMT2A | |
| SCHEMBL24110969 | 0.86 | PIK3CG (0.39) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL24111007 | 0.84 | ALDH1A1 (0.42) | RAD52KMT2AALOX12USP2LMNA | |
| SCHEMBL24110995 | 0.83 | ALOX12 (0.57) | RAD52KMT2AALOX12USP2 | |
| SCHEMBL23958201 | 0.82 | ALOX12 (0.43) | RAD52KMT2AALOX12JAK1TYK2 | |
| SCHEMBL29738614 | 0.82 | PIK3CD (0.46) | PIK3CDPIK3CBRAD52KMT2AALOX12 | |
| SCHEMBL23958265 | 0.82 | PIK3CD (0.46) | PIK3CDPIK3CBRAD52KMT2AALOX12 | |
| SCHEMBL23958226 | 0.81 | RAD52 (0.45) | PIK3CDRAD52KMT2AALOX12USP2 | |
| SCHEMBL24110973 | 0.80 | ALOX12 (0.47) | RAD52KMT2AALOX12USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | PIK3CD 3088/4885PIK3CB 3727/4885PIK3CA 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.